Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
OBJECTIVE
To evaluate the efficiency of Coleman lipostructure in patients infected with human immunodeficiency virus (HIV).


METHODS
Open-label study and survey.


METHODS
Ambulatory dermatosurgery department of a university hospital.


METHODS
Thirty-three consecutive HIV-infected patients undergoing Coleman lipostructure between 2000 and 2001.


METHODS
Clinical examination, blood tests, and standardized photographs at baseline and 1 year after the lipostructure.


METHODS
Efficiency was assessed by the agreement of 3 independent medical specialists on facial lipodystrophy improvement after surgery and by patient satisfaction.


RESULTS
Facial lipoatrophy was improved in 12 patients (36%; 95% confidence interval, 20%-52%) as judged by all 3 evaluators. Quantity of fat injected (P = .01) and a low serum triglyceride level before surgery (P = .03) were significantly associated with improvement of facial lipoatrophy. Of the 33 patients, 14 (43%) were very satisfied, 17 (50%) were partly satisfied, and 27 (81%) had a better quality of life. The most common comment was that the patient looked better and appeared less ill.


CONCLUSIONS
Our 1-year evaluation of Coleman lipostructure for correction of facial lipoatrophy in HIV-infected patients proved the efficiency of this treatment when measured conservatively by agreement on improvement by 3 independent specialists and demonstrated a patient satisfaction rate of 93%.
Burnouf
Marielle
M
Service de Dermatologie, Hôpital Tarnier-Cochin, Paris, France.
Buffet
Marc
M
Schwarzinger
Michaël
M
Roman
Philippe
P
Bui
Patrick
P
Prévot
Marianne
M
Deleuze
Jean
J
Morini
Jean Pierre
JP
Franck
Nathalie
N
Gorin
Isabelle
I
Dupin
Nicolas
N
D000273:Adipose Tissue / Q000637:transplantation*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D008060:Lipodystrophy / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D014182:Transplantation, Autologous / Q000009:adverse effects; D016896:Treatment Outcome